Telemedicine care is an innovative healthcare delivery approach to help overcome difficulties with access to care. We sought to compare pregnancy outcomes with in-person and telemedicine Maternal-Fetal Medicine consultation in women with gestational diabetes mellitus (GDM). STUDY DESIGN: This is a retrospective cohort study of 542 pregnant women with GDM who underwent Maternal-Fetal Medicine consultation between 2016 and 2017. GDM management included physician consultation, medical nutrition therapy counseling by a certified diabetes educator, and weekly glycemic surveillance for both telemedicine and in-person groups. We compared baseline maternal characteristics and pregnancy outcomes based on the type of care. RESULTS: Telemedicine management was performed in 88 (16%) of women with GDM. Women undergoing telemedicine management were younger (29.6 vs 32.2, p<0.001), more likely to be obese (71.6 vs 55%, p¼0.02), and to actively smoke (22.7 vs 11.1, p¼0.01), but there were no differences in gestational age at GDM diagnosis (23.7 vs 25.1 weeks, p¼0.06). Need for pharmacologic therapy was similar in both groups (53.4 vs. 54.8%, p¼0.8). Also, mean fasting (100.5 vs 98.7 mg/dL, p¼0.4) and postprandial (130.8 vs 129.9 mg/dL, p¼0.7) glucose values were similar in women undergoing telemedicine and in-person consultation. Pregnancy outcomes did not differ by management type including preterm birth, hypertensive disorders of pregnancy and cesarean delivery. Neonatal outcomes were similar including NICU admission (17.1 vs. 25.2%, p¼0.1) and composite neonatal morbidity (52.3 vs. 45.2%, p¼0.2) in women with GDM undergoing telemedicine and in-person management. CONCLUSION: We found no difference in pregnancy outcomes in women with GDM who underwent telemedicine or in-person management. Our findings suggest a potential role for telemedicine care in the management of women with GDM. OBJECTIVE: Based on data from non-pregnant women, American Diabetes Association (ADA) recommends long-acting basal analogs (glargine or detemir) be used instead of intermediate-acting insulin (neutral protamine hagedorn [NPH]) to reduce adverse outcomes in type 2 diabetic (T2DM) (Diabetes Care, 2018). However, in pregnant women with T2DM there is a paucity of reports focused exclusively on T2DM. The aim of this study was to compare whether basal insulin analogs reduces rate of composite neonatal morbidity (CNM) and maternal adverse outcomes compared to NPH in women with T2DM. STUDY DESIGN: A retrospective cohort study of all women with T2DM and singleton pregnancy (March 2012 to May 2018) managed at a single tertiary center. Exclusion criteria were known major anomalies, diabetic nephropathy or proliferative retinopathy. The primary outcome was a CNM of any of the following: large for gestational age, shoulder dystocia, NICU admission, hypoglycemia (BS< 40 mg/dL in the first 24 hours of life or <50 mg/dL after 24 hours or requiring medical therapy) or RDS. Secondary outcomes were rates of maternal hypoglycemia events, hypertensive disorders, admission for glucose control, preterm birth (< 37 wks) and primary cesarean delivery. Adjusted relative risk (aRR) and 95% confidence intervals (CI) were calculated. RESULTS: Of 233 women with T2DM, 114 (49%) were treated with basal insulin analogs and 119 (51%) with NPH. Table 1 compares demographic and clinical characteristics. Significant differences on univariate analysis are bolded. The rate of CNM was similar between groups (73% vs 60%, aRR 1.16, 95% CI 0.90-1.49). Basal insulin treatment was associated with a lower risk for a primary cesarean delivery compared to NPH (21% vs 36%, aRR 0.43; 95% CI 0.24-0.76). There were no differences in the rates of maternal hypoglycemic events, admission for glucose control, preeclampsia or preterm birth between the groups (Table2). CONCLUSION: The rate of CNM, neonatal or maternal hypoglycemia-were similar for T2DM managed with either basal or NPH insulin regimen. Since this is a retrospective study, a randomized trial enrolling patients with T2DM prior to 20 weeks of gestation and comparing short and long-term maternal and neonatal outcomes between the two treatment regimens is warranted.
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